Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedcentric Regulatory News (RCN)

Share Price Information for Redcentric (RCN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 127.25
Bid: 126.00
Ask: 128.50
Change: 0.00 (0.00%)
Spread: 2.50 (1.984%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 127.25
RCN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on forensic review and remedial action plan

13 Dec 2016 15:07

RNS Number : 7479R
Redcentric PLC
13 December 2016
 

 

13 December 2016

Redcentric plc

("Redcentric" or the "Company")

 

Update on forensic review and remedial action plan

 

Redcentric (AIM:RCN) provides the following update on the progress made with its forensic review previously announced on 7 November 2016.

 

Initial findings from the forensic review 

 

As previously announced, following an internal review by the Company's audit committee in relation to the interim results for the six months ended 30 September 2016, misstated accounting balances in the Group's balance sheet were discovered. Redcentric promptly appointed Deloitte LLP ("Deloitte") and Nabarro LLP ("Nabarro") to carry out an independent forensic review.

 

The forensic review and management's initial findings are as follows.

 

• Net assets impairment: The cumulative overstatement of net assets and profits after tax up to 30 September 2016 is approximately £20.8 million. The current position is that approximately £5.9 million of this misstatement (£4.7 million at the EBITDA level) arose in the six months ended 30 September 2016 and will be reflected in the Company's interim results when they are published this month. The remaining £14.9 million misstatement relates to periods prior to and including the year ended 31 March 2016. To date there has been no evidence of theft and the misstatements are attributable to profit overstatement over a number of years with revenues being overstated and costs understated in broadly equal proportions.

 

• Net debt: As previously reported, the net debt position for both 31 March 2016 and 30 September 2016 is materially higher than originally reported. As at 31 March 2016, net debt was £37.8 million and as at 30 September 2016 net debt was £34.4 million.

 

However, the net debt position as at the period ends mentioned above are not representative because creditors had been significantly stretched at those dates. The average month end net debt position over the past eight months to 30 November 2016 was £42.0 million. This is expected to reduce as billing and debtor collection processes are improved.

 

Banking covenants

  

As noted in the announcement on 7 November 2016, the Company has recalculated its historic banking covenants due to the impact of various accounting adjustments. The Company is pleased to report that it has secured waivers from its Banks in relation to historic covenants such that it is fully compliant with its facilities. The Banks remain supportive of Redcentric and constructive discussions are ongoing in relation to the agreement of future covenant levels which reflect management's business plan.

 

Remedial action plan

 

As well as promptly appointing Deloitte and Nabarro to carry out the independent forensic review, management have also prepared and are executing a remedial plan of action.

 

Some important first steps have been made. These include the appointment of Peter Brotherton as Chief Financial Officer and Julian Llewellyn as Interim CFO. Both are based at Redcentric's headquarters in Harrogate. A full review of the entire finance function is underway, being directly led by Peter Brotherton.

 

A number of initial improvements have already been made including changes to billing and credit control management systems and processes. The restructuring of the finance function will continue as necessary.

 

Interim results announcement and outlook

 

The Company will report its interim results before 31 December 2016.

 

The Company currently expects to report for the six months ended 30 September 2016 revenue of approximately £53.0 million and EBITDA* of approximately £9.1 million. Given the recurrent nature of a majority of the Group's revenue, being in excess of 80% of total Group revenue, the Board believes that this performance is indicative of the performance for the second half of the year. The sales pipeline remains strong at approximately £93.0 million and the H1 sales targets were exceeded, incorporating 38 new client wins.

 

Given the increase in the Company's net debt position, the Board has resolved not to declare an interim dividend. With an anticipated improvement in net debt, the Board will review the Company's dividend policy at the time of the full-year results.

 

The Company has been very encouraged and appreciative of the supportive response from its employees, clients and prospective clients. The Company is focused on completing the matters outstanding in response to the forensic review, reporting the interim results and engaging with our valued clients and staff.

 

This announcement contains inside information.

 

 Enquiries:

 

Redcentric plc

via Tulchan Communications

Fraser Fisher, Chief Executive Officer

 

Peter Brotherton, Chief Financial Officer

 

 

 

Tulchan

+44 (0)20 7353 4200

James Macey White / Matt Low

 

 

 

Numis Securities Limited - Nomad & Joint Broker

+44 (0)20 7260 1000

Simon Willis / Ben Stoop / Oliver Hardy

 

 

 

finnCap Ltd - Joint Broker

+44 (0)20 7220 0500

Stuart Andrews / Rhys Williams

 

 

* Earnings before interest, tax, depreciation, amortisation of acquired intangibles, transaction and integration costs and share based payments.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFIEFELVLIR
Date   Source Headline
20th Mar 202412:30 pmRNSExercise of Options
4th Mar 20244:00 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSDirector/PDMR Shareholding
13th Feb 202412:30 pmRNSDirectorate Change
30th Jan 20244:30 pmRNSDirector/PDMR Shareholding
25th Jan 20244:45 pmRNSDirector/PDMR Shareholding
24th Jan 20246:20 pmRNSExercise of Options
23rd Jan 20244:32 pmRNSDirector/PDMR Shareholding
19th Jan 20247:00 amRNSShare issue in connection with the FY23 Dividend
17th Jan 20245:00 pmRNSDirector/PDMR Shareholding
15th Jan 20244:00 pmRNSDirector/PDMR Shareholding
11th Jan 20249:45 amRNSDirector/PDMR Shareholding
8th Jan 20244:00 pmRNSDirector/PDMR Shareholding
4th Jan 20241:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20249:00 amRNSDirector/PDMR Shareholding
29th Dec 20237:00 amRNSExercise of Options
27th Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 202312:00 pmRNSDirector/PDMR Shareholding
18th Dec 20234:30 pmRNSDirector/PDMR Shareholding
13th Dec 20234:30 pmRNSDirector/PDMR Shareholding
13th Dec 20237:00 amRNSExercise of Options
11th Dec 202311:00 amRNSDirector/PDMR Shareholding
6th Dec 20237:00 amRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSDirector/PDMR Shareholding
22nd Nov 20237:00 amRNSDirectorate Change
22nd Nov 20237:00 amRNSHalf Year Results
20th Oct 20231:23 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSExercise of Options
3rd Oct 20237:00 amRNSSave As You Earn Share Option Scheme
28th Sep 20234:00 pmRNSResult of AGM
20th Sep 20234:08 pmRNSGrant of Options and Director/PDMR Shareholding
4th Sep 20237:00 amRNSPublication of Annual Report and Notice of AGM
24th Aug 20237:00 amRNSPreliminary results announcement FY23
17th Aug 20237:00 amRNSNotice of Results
17th Jul 20237:00 amRNSUpdate on Annual Results
28th Apr 20235:08 pmRNSHolding(s) in Company
25th Apr 20237:01 amRNSDirectorate Change
25th Apr 20237:00 amRNSTrading Update
31st Mar 20233:14 pmRNSHolding(s) in Company
22nd Feb 20237:00 amRNSExercise of Options
8th Feb 20237:00 amRNSExercise of Options
11th Jan 20237:00 amRNSExercise of Options
30th Dec 20227:00 amRNSExercise of Options
12th Dec 20227:00 amRNSExercise of Options
8th Dec 20227:00 amRNSHalf Year Results
29th Nov 20223:09 pmRNSHolding(s) in Company
17th Nov 20222:46 pmRNSHolding(s) in Company
15th Nov 20227:00 amRNSTrading Update
2nd Nov 20227:00 amRNSExercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.